Use of simulated intestinal fluid for Caco-2 permeability assay of lipophilic drugs

被引：69

作者：

Fossati, Lina ^{[1
]}

Dechaume, Rachel ^{[1
]}

Hardillier, Emmanuel ^{[1
]}

Chevillon, Delphine ^{[1
]}

Prevost, Colette ^{[1
]}

Bolze, Sebastien ^{[1
]}

Maubon, Nathalie ^{[1
]}

机构：

[1] Labs Fournier, Preclin Candidate Select Unit, F-21121 Daix, France

来源：

INTERNATIONAL JOURNAL OF PHARMACEUTICS | 2008年 / 360卷 / 1-2期

关键词：

Caco-2; cells; absorption assay; FaSSIF; transport; lipophilic acid drugs;

D O I：

10.1016/j.ijpharm.2008.04.034

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

The most commonly used method to assess intestinal permeability is the measurement of compound flux across a Caco-2 cells monolayer by using Hanks balanced salt solution (HBSS)-like buffers. Nevertheless, lipophilic acid drugs are poorly or not at all soluble in these types of buffers and their adsorption on the transwell plate is commonly observed. To reduce adsorption and increase solubility, permeability assays need to be developed in conditions other than classic conditions for lipophilic compounds. The best model to increase recovery of lipophilic compounds was determined as fasted state simulated intestinal fluid (FaSSIF) in the apical compartment and HBSS with 1% bovine serum albumin (BSA) in basolateral compartment. This model allows a correlation between absorption on Caco-2 cells and absorbed fraction in humans. For 35 compounds, only 2 outliers were observed in the Caco-2 assay using the FaSSIF model. These two outliers were the same outlier compounds as those observed with a classic Caco-2 method. Furthermore, a permeability assay of Pgp substrates evidenced efflux transport in both models and addition of a Pgp inhibitor suppressed Pgp efflux transport. FaSSIF in the apical compartment and HBSS with 1 % BSA in the basolateral compartment is the model of choice to predict in vivo absorption for lipophilic acid drugs. (c) 2008 Elsevier B.V. All rights reserved.

引用

页码：148 / 155

页数：8

共 39 条

[1] EPITHELIAL TRANSPORT OF DRUGS IN CELL-CULTURE .7. EFFECTS OF PHARMACEUTICAL SURFACTANT EXCIPIENTS AND BILE-ACIDS ON TRANSEPITHELIAL PERMEABILITY IN MONOLAYERS OF HUMAN INTESTINAL EPITHELIAL (CACO-2) CELLS [J].

ANDERBERG, EK ;

NYSTROM, C ;

ARTURSSON, P .

JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (09) :879-887

[2] Intestinal drug absorption and metabolism in cell cultures: Caco-2 and beyond [J].

Artursson, P ;

Borchardt, RT .

PHARMACEUTICAL RESEARCH, 1997, 14 (12) :1655-1658

[3] CORRELATION BETWEEN ORAL-DRUG ABSORPTION IN HUMANS AND APPARENT DRUG PERMEABILITY COEFFICIENTS IN HUMAN INTESTINAL EPITHELIAL (CACO-2) CELLS [J].

ARTURSSON, P ;

KARLSSON, J .

BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 175 (03) :880-885

[4]

ARTURSSON P, 1991, CRIT REV THER DRUG, V8, P305

[5] THE USE OF CULTURED EPITHELIAL AND ENDOTHELIAL-CELLS FOR DRUG TRANSPORT AND METABOLISM STUDIES [J].

AUDUS, KL ;

BARTEL, RL ;

HIDALGO, IJ ;

BORCHARDT, RT .

PHARMACEUTICAL RESEARCH, 1990, 7 (05) :435-451

[6] The influence of donor and reservoir additives on Caco-2 permeability and secretory transport of HIV protease inhibitors and other lipophilic compounds [J].

Aungst, BJ ;

Nguyen, NH ;

Bulgarelli, JP ;

Oates-Lenz, K .

PHARMACEUTICAL RESEARCH, 2000, 17 (10) :1175-1180

[7] Drug liposome partitioning as a tool for the prediction of human passive intestinal absorption [J].

Balon, K ;

Riebesehl, BU ;

Müller, BW .

PHARMACEUTICAL RESEARCH, 1999, 16 (06) :882-888

[8]

BIRCHER J, 1999, KLINISCH PHARMAKOLOG

[9] Expression of drug-metabolizing enzymes, nuclear transcription factors and ABC transporters in Caco-2 cells [J].

Borlak, J ;

Zwadlo, C .

XENOBIOTICA, 2003, 33 (09) :927-943

[10] Profound effect of plasma protein binding on the polarized transport of furosemide and verapamil in the Caco-2 model [J].

Chung, SM ;

Park, EJ ;

Swanson, SM ;

Wu, TC ;

Chiou, WL .

PHARMACEUTICAL RESEARCH, 2001, 18 (04) :544-547

← 1 2 3 4 →